In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Arrowhead Pharmaceuticals, with a price target of $48.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Ulz has given his Hold rating due to a combination of factors surrounding Arrowhead Pharmaceuticals’ current position and future prospects. The recent data from a competitor’s study on an obesity treatment provides a positive outlook for Arrowhead’s own obesity portfolio, which targets similar pathways. However, while the competitor’s results are promising, Arrowhead’s clinical trials are still in early phases, with significant updates not expected until later in 2026.
Despite the encouraging validation from the competitor’s study, the uncertainty surrounding the outcomes of Arrowhead’s trials and the timeline for data release contribute to a cautious approach. The Hold rating reflects a balanced view, acknowledging the potential of Arrowhead’s pipeline while also considering the risks and time required for further development and validation of their treatments.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.